Literature DB >> 22784315

The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII.

P Lapalud1, T Ali, C Cayzac, E Mathieu-Dupas, H Levesque, C Pfeiffer, J Balicchi, Y Gruel, J Y Borg, J F Schved, C Granier, G Lavigne-Lissalde.   

Abstract

BACKGROUND: Acquired hemophilia A (AHA) is a severe life-threatening autoimmune disease due to the development of autoantibodies that neutralize the procoagulant activity of factor VIII (FVIII). In rare cases, AHA occurs in the postpartum period as a serious complication of an otherwise normal pregnancy and delivery. Due to its rarity, little is known about the features of the antibody response to FVIII in AHA.
OBJECTIVES: Our study wanted to (i) determine the epitope specificity and the immunoglobulin (Ig) subclasses of anti-FVIII autoantibodies in plasma samples from a large cohort of AHA patients, and (ii) compare the epitope specificity of anti-FVIII autoantibodies in plasma samples from postpartum AHA and other AHA patients. PATIENTS/
METHODS: Seventy-three plasma samples from patients with postpartum AHA (n = 10) or associated with malignancies (n = 16) or autoimmune diseases (n = 11) or without underlying disease (n = 36) were analyzed with three multiplexed assays. RESULTS AND
CONCLUSIONS: Our results showed a stronger response against the A1a1-A2a2-B fragments of FVIII and more specifically against the A1a1 domain in patients with postpartum AHA than in the other AHA groups (P < 0.01). Moreover, although IgG4 was the predominant IgG subclass in all groups, anti-A1a1-A2a2-B and anti-A1a1 domain autoantibodies of the IgG(1) and IgG3 subclasses were more frequently detected in postpartum AHA than in the other AHA groups. These findings support the involvement of the Th1-driven response in the generation of autoantibodies in women with postpartum AHA compared with the other groups of AHA patients in whom production of Th2-driven IgG4 was predominant.
© 2012 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22784315     DOI: 10.1111/j.1538-7836.2012.04850.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  2 in total

1.  Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

Authors:  Joerg Kahle; Aleksander Orlowski; Diana Stichel; John F Healey; Ernest T Parker; Marc Jacquemin; Manuela Krause; Andreas Tiede; Dirk Schwabe; Pete Lollar; Christoph Königs
Journal:  Blood       Date:  2017-05-15       Impact factor: 22.113

2.  Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Authors:  Y Dargaud; A Pavlova; S Lacroix-Desmazes; K Fischer; M Soucie; S Claeyssens; D W Scott; R d'Oiron; G Lavigne-Lissalde; G Kenet; C Escuriola Ettingshausen; A Borel-Derlon; T Lambert; G Pasta; C Négrier
Journal:  Haemophilia       Date:  2016-01       Impact factor: 4.287

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.